Here are 1-3 brief analogies for Stoke Therapeutics (STOK):

• An earlier-stage Ionis Pharmaceuticals, but uniquely focused on using RNA-based medicines to boost protein production for severe genetic diseases.
• Like Alnylam Pharmaceuticals, but instead of using RNA to silence genes, Stoke uses RNA-based therapies to increase protein expression to treat genetic disorders.

• STK-001: A lead clinical candidate currently in Phase I/IIa trials for treating Dravet syndrome.
• STK-002: A preclinical candidate being developed to treat autosomal dominant optic atrophy.
• RNA-based medicines (through Acadia collaboration): Potential future therapies developed in collaboration with Acadia Pharmaceuticals targeting severe and rare genetic neurodevelopmental diseases.

Stoke Therapeutics (STOK) is an early-stage biopharmaceutical company focused on the development of novel antisense oligonucleotide (ASO) medicines. As such, its primary "customers" at this stage of development are not end-users (patients) or direct healthcare providers, but rather pharmaceutical partners.

Based on the provided information, its major customer is:

• Acadia Pharmaceuticals Inc. (ACAD)

This relationship is described as a license and collaboration agreement for the discovery, development, and commercialization of novel RNA-based medicines.

Ian F. Smith, Chief Executive Officer & Director

Ian F. Smith was appointed permanent Chief Executive Officer and principal executive officer of Stoke Therapeutics in October 2025, having served as interim CEO since March 2025 and as a board member since September 2023. He has over 30 years of finance and operations experience in the biotechnology industry. Prior to joining Stoke, Smith served as Executive Vice President, Chief Operating Officer, and Chief Financial Officer of Vertex Pharmaceuticals from 2001 to 2019. He was also a partner in the Life Science and Technology Practice of Ernst & Young LLP. Smith currently holds executive chairman roles at Solid Biosciences and Rivus Pharmaceuticals, and serves on the Boards of Directors for Foghorn Therapeutics, Alkeus Therapeutics, Odyssey Therapeutics, and Areteia Therapeutics.

Tommy Leggett, Chief Financial Officer

Tommy Leggett was appointed Chief Financial Officer of Stoke Therapeutics in April 2024. He brings over two decades of experience as a biotechnology executive, board member, and investment banker, having led financial strategy and secured financing for numerous life science companies. Before joining Stoke, Leggett served as CFO at Affinia Therapeutics. He was also CFO at Black Diamond Therapeutics, where he managed the company's Series C financing and initial public offering (IPO), and CFO at Axcella Health, where he helped raise $156 million across three financings, including an IPO. Earlier in his career, Leggett spent more than a decade as an investment banker for the healthcare groups at J.P. Morgan Securities, Lazard Frères & Company, and UBS Securities. He is currently a member of the board of directors of Clover Biopharmaceuticals, Ltd.

Barry Ticho, M.D., Ph.D., FACC, Chief Medical Officer

Dr. Barry Ticho serves as the Chief Medical Officer at Stoke Therapeutics. He holds both an M.D. and a Ph.D. and is a Fellow of the American College of Cardiology (FACC).

Isabel Aznarez, Ph.D., Senior Vice President, Head of Research and Co-Founder

Dr. Isabel Aznarez is a co-founder of Stoke Therapeutics and currently holds the position of Senior Vice President and Head of Research. She plays a key role in the company's scientific platform and discovery efforts.

Jonathan Allan, J.D., General Counsel

Jonathan Allan serves as the General Counsel of Stoke Therapeutics. He is responsible for the company's legal matters and holds a Juris Doctor degree.

The key risks to Stoke Therapeutics (STOK) are primarily associated with the inherent uncertainties of developing novel biopharmaceutical products.

1. Clinical Trial Failure: As an early-stage biopharmaceutical company, Stoke Therapeutics' valuation and future prospects heavily rely on the successful outcome of its clinical trials. Its lead candidate, STK-001 (zorevunersen), is currently in a global Phase 3 study for Dravet syndrome, while STK-002 is in a Phase 1 study for Autosomal Dominant Optic Atrophy (ADOA). Drug development involves a high degree of risk, and only a small percentage of research and development programs ultimately result in a commercialized product. Positive results in early-stage trials, such as the completed Phase 1/2a for STK-001, do not guarantee success in later-stage or larger-scale clinical trials, nor do they ensure regulatory approval. The failure of these key trials to confirm earlier data, or the requirement for longer and costlier paths to approval, represents a significant risk to the company.
2. Regulatory Approval Challenges: Even if clinical trials demonstrate favorable efficacy and safety, there is no guarantee that regulatory bodies, such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or Japan's Pharmaceuticals and Medical Devices Agency (PMDA), will grant approval for Stoke's product candidates. The regulatory process is complex and can be lengthy, with potential for unexpected delays or the demand for additional data, which could further increase development costs and postpone market entry.
3. Intense Competition and Commercialization Hurdles: Stoke Therapeutics operates in a highly competitive pharmaceutical landscape. The company competes with larger, more established pharmaceutical and biotechnology firms, including giants in the RNA and gene therapy space such as Ionis Pharmaceuticals and Alnylam, which possess approved products, substantial revenue streams, and extensive manufacturing capabilities. Additionally, Stoke faces competition from companies developing other therapeutic modalities for the same diseases it targets, including Dravet syndrome. Even if a drug receives regulatory approval, successful commercialization requires significant resources for manufacturing, marketing, and distribution, which could be challenging against competitors with greater financial and operational strengths.

Stoke Therapeutics' main products target the following addressable markets:

• STK-001 for Dravet syndrome: The market for Dravet syndrome treatments across the seven major markets (United States, Germany, France, the United Kingdom, Italy, Spain, and Japan) reached an estimated USD 402.4 million in 2024 and is projected to grow to USD 854.0 million by 2035. Globally, the Dravet Syndrome market was valued at USD 411.53 million in 2024 and is expected to reach USD 923.76 million by 2033, growing at a compound annual growth rate (CAGR) of 9.4% during the forecast period (2026–2033). Another global projection indicates the Dravet Syndrome market grew from USD 800.08 million in 2025 to USD 865.96 million in 2026, with an expected growth to USD 1.45 billion by 2032.
• STK-002 for autosomal dominant optic atrophy: The global optic nerve atrophy treatment market, which includes autosomal dominant optic atrophy (ADOA), is estimated at USD 2.75 billion in 2025 and is expected to reach approximately USD 5.87 billion by 2034, with a CAGR of 8.85%. The broader global Optic Atrophy Management Market is projected to be valued at USD 8.82 billion in 2025 and is anticipated to reach USD 14.37 billion by 2035, reflecting a CAGR of 5.0%. Another report states that the global optic atrophy management market is projected to grow from USD 8.91 billion in 2025 to USD 9.51 billion in 2026, and is expected to reach USD 12.32 billion by 2030, with a CAGR of 6.7%.

Expected Drivers of Future Revenue Growth for Stoke Therapeutics (STOK)

Over the next 2-3 years, Stoke Therapeutics' revenue growth is expected to be primarily driven by the following factors:

• Advancement and Potential Commercialization of Zorevunersen (STK-001) for Dravet Syndrome: Stoke Therapeutics' lead clinical candidate, zorevunersen (STK-001), is currently in a global Phase 3 study (EMPEROR) for the treatment of Dravet syndrome. Enrollment for this pivotal trial is anticipated to be completed in the second quarter of 2026, with a data readout expected by mid-2027. This data is intended to support the initiation of a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the first half of 2027, potentially leading to regulatory approval and subsequent commercialization within Stoke's exclusive territories (U.S., Canada, and Mexico). Furthermore, a collaboration with Biogen grants Biogen commercialization rights for zorevunersen outside these territories, which includes potential milestone payments and tiered royalties on future sales for Stoke. The publication of positive clinical data for zorevunersen in The New England Journal of Medicine in March 2026 further supports its potential as a disease-modifying treatment.
• Milestone Payments from the Acadia Pharmaceuticals Collaboration: Stoke Therapeutics has an ongoing license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for severe and rare genetic neurodevelopmental diseases, including SYNGAP1 syndrome and Rett syndrome (MECP2). Under the terms of this agreement, Stoke received an upfront payment and is eligible to receive up to $907 million in development, regulatory, first commercial sales, and sales milestones, as well as royalties on future sales. As these partnered programs advance through various stages of research and development, Stoke can expect to recognize additional milestone payments, contributing to its revenue growth.
• Expansion of Pipeline and New Partnerships Leveraging the TANGO Platform: Stoke Therapeutics' proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform is designed to precisely upregulate protein expression, offering a broad applicability for treating various genetic diseases. While STK-002 for autosomal dominant optic atrophy is in preclinical stages, the successful validation of the TANGO platform through the ongoing clinical development of STK-001 and existing partnerships may attract new strategic collaborations. These potential future partnerships could lead to additional upfront payments and milestone revenue, similar to the existing agreements with Biogen and Acadia, as new programs are initiated and progressed within the next few years.

Share Repurchases

• Stoke Therapeutics did not report any share repurchases over the last 3-5 years.

Share Issuance

• Stoke Therapeutics issued common stock valued at approximately $10.66 million in the trailing twelve months ending June 30, 2025.
• The company issued common stock amounting to approximately $131.09 million in 2024, $53.01 million in 2023, and $46.41 million in 2022.
• The number of shares outstanding has steadily increased from 0.033 billion in December 2020 to 0.058 billion by June 2025.

Inbound Investments

• Stoke Therapeutics established a strategic collaboration with Biogen in February 2025, granting Biogen exclusive commercialization rights for zorevunersen outside of the U.S., Canada, and Mexico.
• The company recognized $10.6 million in revenue for Q3 2025, an increase from $4.9 million in Q3 2024, driven by contractual obligations under agreements with Acadia Pharmaceuticals and Biogen.
• In Q4 2024, operating revenue reached $22,614,000, significantly higher than prior quarters, which suggests a boost from milestone payments or upfront fees from collaborations.

Capital Expenditures

• In the last 12 months, capital expenditures were -$480,000.
• Stoke Therapeutics invested $132K in capital expenditures in Q3 2025, primarily funding long-term assets and infrastructure.
• The company plans to relocate to a new 98,500 square-foot headquarters in Waltham, Massachusetts, when its current lease ends in late 2026.